Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer

Gynecologic Oncology

Volumn 133, Issue 2, 2014, Pages 346-352

  Bradford, Leslie S ^a,b   Rauh Hain, Alejandro ^a,b   Clark, Rachel M ^a,b   Groeneweg, Jolijn W ^a,b   Zhang, Ling ^a   Borger, Darrell ^a,b   Zukerberg, Lawrence R ^a,b   Growdon, Whitfield B ^a,b   Foster, Rosemary ^a,b   Rueda, Bo R ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Endometrial cancer; PI3K inhibitor; PI3K AKT mTOR pathway

Indexed keywords

BUPARLISIB; CARBOPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CARCINOSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENZYME INHIBITION; FEMALE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WILD TYPE;

ENDOMETRIAL CANCER; PI3K INHIBITOR; PI3K/AKT/MTOR PATHWAY;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CARCINOSARCOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICE; MICE, SCID; MORPHOLINES; MUTATION; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899585031     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.02.022     Document Type: Article

References (38)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. E.J. Robbe, and J.M. Pijnenborg Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis BJOG 115 2008 926 927 [author reply 7]
3. P.G. Rose Endometrial carcinoma N Engl J Med 335 1996 640 649
4. C.E. Humber, J.F. Tierney, R.P. Symonds, M. Collingwood, J. Kirwan, and C. Williams et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration Ann Oncol 18 2007 409 420
5. C.A. Hamilton, M.K. Cheung, K. Osann, L. Chen, N.N. Teng, and T.A. Longacre et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
6. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
7. K.J. Dedes, D. Wetterskog, A. Ashworth, S.B. Kaye, and J.S. Reis-Filho Emerging therapeutic targets in endometrial cancer Nat Rev Clin Oncol 8 2011 261 271
8. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
9. C. Kandoth, N. Schultz, A.D. Cherniack, R. Akbani, Y. Liu, and H. Shen et al. Integrated genomic characterization of endometrial carcinoma Nature 497 2013 67 73
10. K. Shoji, K. Oda, T. Kashiyama, Y. Ikeda, S. Nakagawa, and K. Sone et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas PLoS One 7 2012 e37431
11. F. Janku, J.J. Wheler, A. Naing, V.M. Stepanek, G.S. Falchook, and S. Fu et al. PIK3CA mutations in advanced cancers: characteristics and outcomes Oncotarget 3 2012 1566 1575
12. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, and D.M. Provencher et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 2011 3278 3285
13. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and R.R. Broaddus et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 2010 5415 5419
14. B.M. Slomovitz, and R.L. Coleman The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer Clin Cancer Res 18 2012 5856 5864
15. F. Janku, J.J. Wheler, A. Naing, G.S. Falchook, D.S. Hong, and V. Stepanek et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials Cancer Res 73 2013 276 284
16. M.D. Curley, V.A. Therrien, C.L. Cummings, P.A. Sergent, C.R. Koulouris, and A.M. Friel et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer Stem Cells 27 2009 2875 2883
17. D. Dias-Santagata, S. Akhavanfard, S.S. David, K. Vernovsky, G. Kuhlmann, and S.L. Boisvert et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine EMBO Mol Med 2 2010 146 158
18. K. Garg, R.R. Broaddus, R.A. Soslow, D.L. Urbauer, D.A. Levine, and B. Djordjevic Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible Int J Gynecol Pathol 31 2012 48 56
19. K. Oda, D. Stokoe, Y. Taketani, and F. McCormick High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma Cancer Res 65 2005 10669 10673
20. A. Carracedo, and P.P. Pandolfi The PTEN-PI3K pathway: of feedbacks and cross-talks Oncogene 27 2008 5527 5541
21. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, and D. Smith et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508
22. M. Elkabets, S. Vora, D. Juric, N. Morse, M. Mino-Kenudson, and T. Muranen et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer Sci Transl Med 5 2013 196ra99
23. M.C. Mendoza, E.E. Er, and J. Blenis The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation Trends Biochem Sci 36 2011 320 328
24. H.B. Salvesen, I.S. Haldorsen, and J. Trovik Markers for individualised therapy in endometrial carcinoma Lancet Oncol 13 2012 e353 e361
25. D. Juric, and J. Baselga Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors J Clin Oncol 30 2012 765 766
26. B. Weigelt, P.H. Warne, M.B. Lambros, J.S. Reis-Filho, and J. Downward PI3K pathway dependencies in endometrioid endometrial cancer cell lines Clin Cancer Res 19 2013 3533 3544
27. D.P. English, S. Bellone, E. Cocco, I. Bortolomai, S. Pecorelli, and S. Lopez et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) Am J Obstet Gynecol 209 2013 465.e1 465.e9
28. O. Tredan, I. Treilleux, Q. Wang, N. Gane, D. Pissaloux, and N. Bonnin et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study Target Oncol 8 2012 243 251
29. J.C. Bendell, J. Rodon, H.A. Burris, M. de Jonge, J. Verweij, and D. Birle et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors J Clin Oncol 30 2012 282 290
30. A. Ashworth, C.J. Lord, and J.S. Reis-Filho Genetic interactions in cancer progression and treatment Cell 145 2011 30 38
31. S. Wee, D. Wiederschain, S.M. Maira, A. Loo, C. Miller, and R. deBeaumont et al. PTEN-deficient cancers depend on PIK3CB Proc Natl Acad Sci U S A 105 2008 13057 13062
32. J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, R.A. Franklin, and G. Montalto et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance Oncotarget 3 2012 1068 1111
33. Y.H. Ibrahim, C. Garcia-Garcia, V. Serra, L. He, K. Torres-Lockhart, and A. Prat et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition Cancer Discov 2 2012 1036 1047
34. A. Juvekar, L.N. Burga, H. Hu, E.P. Lunsford, Y.H. Ibrahim, and J. Balmana et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer Cancer Discov 2 2012 1048 1063
35. C.C. Clark, J.N. Weitzel, and T.R. O'Connor Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models Mol Cancer Ther 11 2012 1948 1958
36. W.H. Shen, A.S. Balajee, J. Wang, H. Wu, C. Eng, and P.P. Pandolfi et al. Essential role for nuclear PTEN in maintaining chromosomal integrity Cell 128 2007 157 170
37. K.J. Dedes, D. Wetterskog, A.M. Mendes-Pereira, R. Natrajan, M.B. Lambros, and F.C. Geyer et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors Sci Transl Med 2 2010 53ra75
38. M.D. Forster, K.J. Dedes, S. Sandhu, S. Frentzas, R. Kristeleit, and A. Ashworth et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 2011 302 306